UK Stocks-Factors to watch on September 14
UK Stocks-Factors to watch on September 14 Sept 14 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Monday, with futures FFIc1 up 0.16%.
* ASTRAZENECA: AstraZeneca's AZN.L breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said, a week after the treatment received U.S. approval.
* GSK: GSK GSK.L said it will be shutting down a vaccine factory in Dresden, Germany, in the summer of 2027, citing decreasing demand for traditional egg-based flu vaccines.
* REVOLUT: British fintech Revolut confirmed that sensitive customer information was disclosed to an unauthorized third party after it received fraudulent requests from a legitimate government agency email domain.
* OIL: Oil prices rose over 3%, after new Houthi strikes on Saudi Arabia and Iranian attacks on ships in the Gulf compounded supply concerns following the closure of a key Saudi oil pipeline.
* GOLD: Gold prices eased as a surge in oil prices stoked inflation concerns, boosting expectations that the U.S. Federal Reserve may raise interest rates at its policy meeting this week.
* METALS: Copper fell, extending losses from last week, as uncertainty over potential U.S. tariffs on refined copper continued to weigh on sentiment and cloud the outlook for tariff-driven inventory flows.
* FTSE: Financials led London's FTSE indexes slightly higher on Friday, ending a week-long sell-off caused by nervousness about the economic impact of the U.S.-Israeli war on Iran and high oil prices.
* For more on the factors affecting European stocks, please click on: LIVE/
TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB
(Compiled by Neeshita Beura in Bengaluru)
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines